Letter
Oncology
Shuling Chen, Jiaxin Li, Aoran Dong, Zelong Liu, Meiyan Zhu, Meng Jin, Guangyan Wei, Shuang Wu, Yan Wang, Yong Chen, Zhenwei Peng
Summary: This study compared the efficacy and safety of combination therapy with immunotherapy and radiotherapy versus chemotherapy alone for patients with locally advanced pancreatic adenocarcinoma (LAPC). The combination treatment group showed significant advantages in median overall survival and progression-free survival compared to the chemotherapy alone group. However, the incidence of severe adverse events did not differ significantly between the two groups. Therefore, combination therapy appears to be an effective and safe treatment option for LAPC patients.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Article
Gastroenterology & Hepatology
Volker Kunzmann, Jens T. Siveke, Hana Alguel, Eray Goekkurt, Gabriele Siegler, Uwe Martens, Dirk Waldschmidt, Uwe Pelzer, Martin Fuchs, Frank Kullmann, Stefan Boeck, Thomas J. Ettrich, Swantje Held, Ralph Keller, Ingo Klein, Christoph-Thomas Germer, Hubert Stein, Helmut Friess, Marcus Bahra, Ralf Jakobs, Ingo Hartlapp, Volker Heinemann
Summary: The study compared the efficacy and safety of two multidrug induction chemotherapy regimens for locally advanced pancreatic cancer and found that nab-paclitaxel plus gemcitabine is similarly active and safe as nab-paclitaxel plus gemcitabine followed by FOLFIRINOX. However, further evidence is needed to determine whether this translates into improved overall survival for patients.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Ilario Giovanni Rapposelli, Andrea Casadei-Gardini, Caterina Vivaldi, Giulia Bartolini, Laura Bernardini, Alessandro Passardi, Giovanni Luca Frassineti, Valentina Massa, Alessandro Cucchetti
Summary: The study found that FFX and GN have equivalent efficacy in first-line treatment of metastatic pancreatic cancer, but differ in safety profiles. Anemia was more frequent in the GN group, while higher occurrences of vomiting and diarrhea were reported in the FFX group.
Review
Oncology
Francesco Di Costanzo, Federica Di Costanzo, Lorenzo Antonuzzo, Ernesto Mazza, Elisa Giommoni
Summary: Choosing the best first-line treatment for metastatic pancreatic cancer is crucial in improving survival rate and quality of life. FOLFIRINOX and Nab-p plus Gem have been recognized as the most effective treatment regimens. FOLFIRINOX shows better efficacy but higher toxicity.
Article
Oncology
Satoshi Kobayashi, Motoko Suzuki, Makoto Ueno, Yuta Maruki, Naohiro Okano, Akiko Todaka, Masato Ozaka, Kunihiro Tsuji, Kazuhiko Shioji, Keitaro Doi, Yasushi Kojima, Hidetaka Tsumura, Kazunari Tanaka, Hajime Higuchi, Ken Kawabe, Hiroshi Imaoka, Tatsuya Yamashita, Haruo Miwa, Hiroaki Nagano, Shiho Arima, Hideyuki Hayashi, Atsushi Naganuma, Hironori Yamaguchi, Terumasa Hisano, Kumiko Umemoto, Shuji Ishii, Koji Nakashima, Rei Suzuki, Yohei Kitano, Toshihiro Misumi, Junji Furuse, Hiroshi Ishii
Summary: This study investigated the efficacy and safety of Gemcitabine plus nab-paclitaxel (GnP) compared to other treatments in older adults with unresectable pancreatic cancer (uPC). The results showed that GnP was more effective than Gem in patients aged 76 years and older, despite a higher incidence of severe adverse events.
Article
Oncology
Yuan Zong, Jiajia Yuan, Zhi Peng, Ming Lu, Xicheng Wang, Lin Shen, Jun Zhou
Summary: The study compared the efficacy and safety of nab-paclitaxel plus S-1 with nab-paclitaxel plus gemcitabine in first-line chemotherapy for patients with PDAC. Despite comparable efficacy, the nab-P/S combination showed improved safety profile with reduced risks of hematological toxicity, liver injury, and rash. There were no significant differences in primary and secondary endpoints between the two treatment arms.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Ilaria Trestini, Luisa Carbognin, Umberto Peretti, Isabella Sperduti, Alberto Caldart, Daniela Tregnago, Alice Avancini, Alessandra Auriemma, Giulia Orsi, Sara Pilotto, Luca Frulloni, Gabriele Capurso, Emilio Bria, Michele Reni, Giampaolo Tortora, Michele Milella
Summary: This retrospective study investigated the use of pancreatic enzyme replacement therapy (PERT) in advanced pancreatic ductal adenocarcinoma (PDAC) patients undergoing chemotherapy, and found that PERT was associated with significantly prolonged survival and alleviation of maldigestion-related symptoms.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Masato Ozaka, Kohei Nakachi, Satoshi Kobayashi, Akihiro Ohba, Hiroshi Imaoka, Takeshi Terashima, Hiroshi Ishii, Junki Mizusawa, Hiroshi Katayama, Tomoko Kataoka, Takuji Okusaka, Masafumi Ikeda, Naoki Sasahira, Haruo Miwa, Eishiro Mizukoshi, Naohiro Okano, Nobumasa Mizuno, Tomohisa Yamamoto, Yoshito Komatsu, Akiko Todaka, Ken Kamata, Masayuki Furukawa, Nao Fujimori, Akio Katanuma, Yukiko Takayama, Hidetaka Tsumura, Haruhiko Fukuda, Makoto Ueno, Junji Furuse
Summary: The aim of this study was to compare the efficacy of mFOLFIRINOX with that of GnP for LAPC. The results showed that GnP had better response rate, CA19-9 response, and mild gastrointestinal toxicities, making it a candidate for a subsequent phase III trial.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
T. Seufferlein, W. Uhl, M. Kornmann, H. Alguel, H. Friess, A. Koenig, M. Ghadimi, E. Gallmeier, D. K. Bartsch, M. P. Lutz, R. Metzger, K. Wille, B. Gerdes, C. C. Schimanski, F. Graupe, V. Kunzmann, I. Klein, M. Geissler, L. Staib, D. Waldschmidt, C. Bruns, U. Wittel, S. Fichtner-Feigl, S. Daum, A. Hinke, L. Blome, A. Tannapfel, A. Kleger, A. W. Berger, A. M. R. Kestler, J. S. Schuhbaur, L. Perkhofer, M. Tempero, A. C. Reinacher-Schick, T. J. Ettrich
Summary: This study aimed to evaluate the efficacy of perioperative or adjuvant chemotherapy with gemcitabine plus nab-paclitaxel in resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that the preoperative chemotherapy group had a higher disease-free survival rate at 18 months compared to the adjuvant chemotherapy group.
ANNALS OF ONCOLOGY
(2023)
Article
Cell Biology
Concetta Panebianco, Federica Pisati, Annacandida Villani, Annapaola Andolfo, Marynka Ulaszewska, Edoardo Bellini, Carmelapia Ferro, Renato Lombardi, Fabrizio Orsenigo, Tiziana Pia Latiano, Beatrice Belmonte, Claudio Tripodo, Francesco Perri, Valerio Pazienza
Summary: Pancreatic cancer has a low survival rate due to late diagnosis and resistance to therapies. The authors studied the effects of a specific probiotic blend on mice with pancreatic cancer and found that it reduced chemotherapy side effects and decreased cancer-associated stromatogenesis. The results suggest that manipulating the microbiota could be a desirable strategy to improve the quality of life and increase the chance of cure for pancreatic cancer patients.
CELL DEATH DISCOVERY
(2023)
Article
Medicine, General & Internal
Juraj Prejac, Dora Tomek Hamzic, Niksa Librenjak, Irma Gorsic, Domina Kekez, Stjepko Plestina
Summary: In first-line treatment of metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine showed improved overall survival and progression-free survival compared to gemcitabine alone. Elderly patients, patients with poorer performance, higher metastatic burden, and liver involvement benefited the most from combination therapy.
Article
Oncology
Simon Zaibet, Vincent Hautefeuille, Edouard Auclin, Astrid Lievre, David Tougeron, Mathieu Sarabi, Marine Gilabert, Julie Wasselin, Julien Edeline, Pascal Artru, Dominique Bechade, Clemence Morin, Agnes Ducoulombier, Julien Taieb, Simon Pernot
Summary: This study evaluates the efficacy and safety of adding Nab-paclitaxel to Gem for metastatic pancreatic adenocarcinoma (mPA) after FOLFIRINOX failure. The results show that Gem-Nab is associated with better disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) compared with Gem alone, but with higher toxicity.
BRITISH JOURNAL OF CANCER
(2022)
Article
Multidisciplinary Sciences
Martina Catalano, Giuseppe Aprile, Raffaele Conca, Roberto Petrioli, Monica Ramello, Giandomenico Roviello
Summary: This study investigated the impact of risk factors such as performance status and comorbidities on the effectiveness of nab-paclitaxel and gemcitabine treatment in patients with metastatic pancreatic cancer. The results showed that patients without risk factors had higher overall survival, and age, performance status, and comorbidities were prognostic factors.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Naminatsu Takahara, Yousuke Nakai, Hironori Ishigami, Kei Saito, Tatsuya Sato, Ryunosuke Hakuta, Kazunaga Ishigaki, Tomotaka Saito, Tsuyoshi Hamada, Suguru Mizuno, Hirofumi Kogure, Hiroharu Yamashita, Hiroyuki Isayama, Yasuyuki Seto, Kazuhiko Koike
Summary: This study investigated the maximum tolerated dose and recommended dose of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel in pancreatic cancer patients with peritoneal metastasis. The results showed the feasibility and potential effectiveness of this treatment regimen as a first-line therapy for pancreatic cancer patients with peritoneal metastasis.
INVESTIGATIONAL NEW DRUGS
(2021)
Article
Medicine, General & Internal
Tanios Bekaii-Saab, Takuji Okusaka, David Goldstein, Do-Youn Oh, Makoto Ueno, Tatsuya Ioka, Weijia Fang, Eric C. Anderson, Marcus S. Noel, Michele Reni, Hye Jin Choi, Jonathan S. Goldberg, Sang Cheul Oh, Chung-Pin Li, Josep Tabernero, Jian Li, Emma Foos, Cindy Oh, Eric Van Cutsem
Summary: In an open-label phase 3 study, it was found that the addition of napabucasin to nab-paclitaxel with gemcitabine did not improve efficacy in patients with previously untreated metastatic pancreatic adenocarcinoma (mPDAC). However, the safety profile of napabucasin was consistent with previous reports. This study reinforced the value of nab-paclitaxel plus gemcitabine as a platform for novel therapeutic approaches in mPDAC.